Source: Eur Respir J 2003; 22: 568
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Braunstein G.L.. Distribution of therapeutic response in asthma control. Eur Respir J 2003; 22: 568

Member's Comments

No comment yet.

Related content which might interest you: Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Impact of omalizumab treatment persistence on asthma control Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Assessing the relative contribution of the asthma control testÔ (ACT) and spirometry in predicting asthma control Source: Eur Respir J 2004; 24: Suppl. 48, 472s Year: 2004 Therapeutic ratios predict asthma control in the ASTROLAB cohort Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017 Improving asthma therapy through targeting more effective control of inflammation - a European consensus Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Predictors of asthma non control Source: Virtual Congress 2020 – Clinical and functional evaluation of asthmatics Year: 2020 Effect of patients‘ characteristics and asthma management on control Source: Eur Respir J 2005; 26: Suppl. 49, 381s Year: 2005 Differences in asthma control and lung function in relation to allergic status Source: Eur Respir J, 53 (6) 1802102; 10.1183/13993003.02102-2018 Year: 2019 Comparison between airway response to high versus low molecular weight agents in occupational asthma Source: Annual Congress 2010 - Occupational asthma Year: 2010 Relationship between asthma control test (ACT) and clinical, functional and inflammatory markers in treated and non treated asthmatics Source: Annual Congress 2008 - Inflammatory biomarkers Year: 2008 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 GOAL (gaining optimal asthma control): a study to assess asthma control Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 The role of Hs-CRP in evaluating asthma severity and asthma control Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010